Abstract

Multidrug-resistant, Gram-negative infection is a major global determinant of morbidity, mortality and cost of care. The advent of nanomedicine has enabled tailored engineering of macromolecular constructs, permitting increasingly selective targeting, alteration of volume of distribution and activity/toxicity. Macromolecules tend to passively and preferentially accumulate at sites of enhanced vascular permeability and are then retained. This enhanced permeability and retention (EPR) effect, whilst recognized as a major breakthrough in anti-tumoral targeting, has not yet been fully exploited in infection. Shared pathophysiological pathways in both cancer and infection are evident and a number of novel nanomedicines have shown promise in selective, passive, size-mediated targeting to infection. This review describes the similarities and parallels in pathophysiological pathways at molecular, cellular and circulatory levels between inflammation/infection and cancer therapy, where use of this principle has been established.

Keywords

NanomedicineVascular permeabilityDrugInflammationMedicineCancerPathophysiologyImmunologyPharmacologyPathologyNanotechnologyInternal medicine

Affiliated Institutions

Related Publications

Publication Info

Year
2012
Type
review
Volume
68
Issue
2
Pages
257-274
Citations
295
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

295
OpenAlex

Cite This

Ernest Azzopardi, Elaine L. Ferguson, David W. Thomas (2012). The enhanced permeability retention effect: a new paradigm for drug targeting in infection. Journal of Antimicrobial Chemotherapy , 68 (2) , 257-274. https://doi.org/10.1093/jac/dks379

Identifiers

DOI
10.1093/jac/dks379